<html><head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8"><script>
function toggleSelectedText(e) {
    if (e.shiftKey) {
        var selection = window.getSelection();
        var range = selection.getRangeAt(0);
        var tags = "p,h1,h2,h3,h4,h5,h6,ul,ol,li,dl,dt,table,tr,td,th,article,main,section,figure,figcaption,aside,section,address,blockquote";
        if (range.commonAncestorContainer.getElementsByTagName) {
            var allWithinRangeParent = range.commonAncestorContainer.querySelectorAll(tags);
        }
        else {
            //var allWithinRangeParent = [range.commonAncestorContainer.closest(tags)];
            var allWithinRangeParent = [range.commonAncestorContainer.parentNode.closest(tags)];
        }

        for (var i=0, el; el = allWithinRangeParent[i]; i++) {
          // The second parameter says to include the element
          // even if it's not fully selected
          if (selection.containsNode(el, true) ) {
              el.classList.toggle('rm-manual');
          }
        }
        window.getSelection().removeAllRanges();
    }
};

//var article = document.body.querySelector('article');
document.onmouseup = toggleSelectedText;
document.captureEvents(Event.MOUSEUP);
</script>

<style>
.rm-manual {
    text-decoration: line-through;
    background-color: #faa;
}
</style>
        </head><body><div> Risque de variole, vaccination et 
bioterrorisme - ScienceDirect JavaScript is disabled on your browser. 
Please enable JavaScript to use all the features on this page. <a href="#screen-reader-main-content">Skip to main content</a> <a href="#screen-reader-main-title">Skip to article</a> <ul class="rm-manual"><li class="rm-manual"><a href="file:///browse/journals-and-books"><span>Journals &amp; Books</span></a></li></ul>
<p class="rm-manual"><a href="file:///user/register?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Register</span></a><a href="file:///user/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Sign in</span></a></p>
<p class="rm-manual"><a href="file:///user/login?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Sign in</span></a><a href="file:///user/register?targetURL=%2Fscience%2Farticle%2Fpii%2FS0755498205838990"><span>Register</span></a></p>
<ul class="rm-manual"><li class="rm-manual"><a href="file:///browse/journals-and-books"><span>Journals &amp; Books</span></a></li></ul>
<ul class="rm-manual"><li class="rm-manual"><a href="https://service.elsevier.com/app/home/supporthub/sciencedirect/" rel="noopener noreferrer"><span>Help</span></a></li></ul>
<p class="rm-manual"><a href="file:///">ScienceDirect</a></p>
<p class="rm-manual"><a href="file:///search">Advanced</a></p>
<h2 class="rm-manual"><a href="file:///science/journal/07554982">La Presse Médicale</a></h2>
<p class="rm-manual"><a href="file:///science/journal/07554982/34/2/part/P2">Volume 34, Issue 2, Part 2</a>, January 2005, Pages 177-184</p>
<p class="rm-manual"><span>Bioterrorisme</span></p>
<h1 class="">
<span>Risque de variole, vaccination et bioterrorisme</span><span>Risk of smallpox, vaccin, biowarfare</span>
</h1>
<p class="rm-manual"><span>Author links open overlay panel</span><a href="#!"><span><span>P.</span><span>Bossi</span></span></a><a href="#!"><span><span>D.</span><span>Garin</span></span></a><a href="#!"><span><span>B.</span><span>Combadière</span></span></a><a href="#!"><span><span>É.</span><span>Rouleau</span></span></a><a href="#!"><span><span>S.</span><span>Rigaudeau</span></span></a><a href="#!"><span><span>B.</span><span>Lebrun-Vignes</span></span></a><a href="#!"><span><span>V.</span><span>Martinez</span></span></a><a href="#!"><span><span>B.</span><span>Autran</span></span></a><a href="#!"><span><span>F.</span><span>Bricaire</span></span></a></p>
<p class="rm-manual"><a href="https://doi.org/10.1016/S0755-4982(05)83899-0" rel="noreferrer noopener">https://doi.org/10.1016/S0755-4982(05)83899-0</a><a rel="noreferrer noopener" href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S0755498205838990&amp;orderBeanReset=true">Get rights and content</a></p>
<h2>Points essentiels</h2>
<p>L’utilisation du virus de la variole comme arme biologique est 
ancienne. Face à la menace bioterriste avérée actuelle, des plans de 
lutte ont été rédigés ; l’un de leurs principaux objectifs repose sur la
 vaccination d’équipes dédiées à la prise en charge de sujets infectés 
et sur le stockage de doses de vaccins suffisantes pour toute la 
population d’un pays.</p>
<p>À la suite de l’éradication mondiale de la variole, la vaccination 
préventive a été arrêtée en France en 1978 pour la primo-vaccination, en
 1984 pour les injections de rappel.</p>
<p>Les différentes souches vaccinales utilisées dans les vaccins de 
première génération sont des vaccins vivants atténués provenant du virus
 de la vaccine dont l’hôte naturel et l’origine demeurent inconnus. Les 
vaccins de seconde et troisième génération sont en cours d’étude; 
l’objectif principal est l’efficacité avec un minimum d’effets 
secondaires.</p>
<p>Les effets indésirables, connus essentiellement pour les vaccins de 
première génération, sont de 2 ordres: les uns, extrêmement rares, 
peuvent engager le pronostic vital; les autres, plus fréquents (10 à 15 %
 des patients) sont bénins.</p>
<p>En situation d’urgence, en présence de cas de variole, il ne devrait 
pas y avoir de contre-indications absolues à la vaccination.</p>
<p>Dans un contexte de bioterrorisme, il ne s’agit pas de réaliser une 
campagne de vaccination de masse de la population (avec ses risques non 
négligeables de décès et d’effets indésirables graves) en l’absence de 
toute menace avérée. En France, 5 niveaux d’alerte ont été définis, 
avec, dans chaque cas, une stratégie vaccinale à adopter.</p>
<dl>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
</dl>
<h2>Key points</h2>
<p>The use of the smallpox virus as a biological weapon is very old. 
Confronted with a high probability of a currennt bioterrorist menace, 
counteracting strategies have been developed. One of the principle aims 
relies on the vaccination of teams dedicated to the management of 
persons infected and the stocking of sufficient doses of vaccine for the
 whole population of a country.</p>
<p>Following worldwide eradication of the disease, preventive 
vaccination was stopped in 1978 in France for the primo-vaccination, and
 in 1984 for repeat vaccinations.</p>
<p>The various strains used in the first generation vaccinations are 
weakened living vaccines from the virus of the vaccine, the natural host
 and origin of which are unknown. Second and third generations vaccines 
are under study; the principle objective is to obtain efficacy with a 
minimum of side effects.</p>
<p>There are two types of adverse events, generally observed with the 
first generation vaccines: the first, extremely rare, can be 
life-threatening; the others, more frequent (10 to 15% of patients) are 
benign.</p>
<p>In emergency situations in the presence of smallpox, there should be no absolute contraindications to vaccination.</p>
<p>In the bioterrorist context, massive vaccination campaigns of the 
population are unadvisable (because of the considerable risk of death 
and severe adverse events) in the absence of any real risk. In France, 5
 levels of alert have been established that permit, in each case, 
definition of the vaccinal strategy to be adopted.</p>
<dl>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
<dt class="rm-manual">•</dt>
</dl>
<p class="rm-manual"><span>Copyright © 2005 Elsevier Masson SAS. All rights reserved.</span></p>
<p class="rm-manual"><span>No articles found.</span></p>
<h2 class="rm-manual">Citing articles</h2>
<p class="rm-manual"><a href="https://plu.mx/plum/a/?doi=10.1016/S0755-4982(05)83899-0">View article metrics</a></p>
<p class="rm-manual"></p><article class="rm-manual"><a href="file:///science/article/pii/S0755498205838990"><span>View full text</span></a></article><p class="rm-manual"></p>
<ul class="rm-manual">
<li class="rm-manual"><a href="https://www.elsevier.com/solutions/sciencedirect" rel="nofollow"><span>About ScienceDirect</span></a></li>
<li class="rm-manual"><a href="file:///customer/authenticate/manra" rel="nofollow"><span>Remote access</span></a></li>
<li class="rm-manual"><a href="https://sd-cart.elsevier.com/?" rel="nofollow"><span>Shopping cart</span></a></li>
<li class="rm-manual"><a href="http://elsmediakits.com/" rel="nofollow"><span>Advertise</span></a></li>
<li class="rm-manual"><a href="https://service.elsevier.com/app/contact/supporthub/sciencedirect/" rel="nofollow"><span>Contact and support</span></a></li>
<li class="rm-manual"><a href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions" rel="nofollow"><span>Terms and conditions</span></a></li>
<li class="rm-manual"><a href="https://www.elsevier.com/legal/privacy-policy" rel="nofollow"><span>Privacy policy</span></a></li>
</ul>
<p class="rm-manual">We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the <a href="https://www.sciencedirect.com/legal/use-of-cookies" rel="nofollow"><span>use of cookies</span></a>.</p>
<p class="rm-manual">Copyright © 2020 Elsevier B.V. or its licensors or contributors. <span>ScienceDirect ® is a registered trademark of Elsevier B.V.</span></p>
<p class="rm-manual">ScienceDirect ® is a registered trademark of Elsevier B.V.</p> </div>
</body></html>